U.S. SECURITIES AND EXCHANGE COMMISSION
                             Washington, D.C. 20549

                                   FORM 10-QSB


         (Mark One)
         [X] QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES
         EXCHANGE ACT OF 1934 FOR THE QUARTERLY PERIOD ENDED MAY 31, 2003.

         OR

         [ ]      TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE
         SECURITIES EXCHANGE ACT OF 1934 FOR THE TRANSITION PERIOD FROM
         ______________ TO ______________

                        COMMISSION FILE NUMBER: 000-31431


                               US BIODEFENSE, INC.
             (Exact name of registrant as specified in its charter)

                         Utah                              33-0052057
        (State or jurisdiction of incorporation          I.R.S. Employer
                    or organization                    Identification No.)

                              13674 E. Valley Blvd.
                             City of Industry 91746
               (Address of principal executive offices) (Zip Code)

                  Registrant's telephone number: (626) 961-8039

                                 Piedmont, Inc.
                           1001 - 17th Street, Suite M
                              Costa Mesa, CA 92626
          (Former Name or Former Address, if Changed Since Last Report)

        Securities registered pursuant to Section 12(b) of the Act: None

           Securities registered pursuant to Section 12(g) of the Act:
                         Common Stock, $0.001 Par Value

Indicate by check mark whether the Registrant (1) has filed all reports required
to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during
the  preceding 12 months (or for such  shorter  period that the  Registrant  was
required to file such reports), and (2) been subject to such filing requirements
for the past 90 days. Yes X No

As of May 31,  2003,  the  Registrant  had  100,932 of common  stock  issued and
outstanding.

Transitional Small Business Disclosure Format (check one): Yes No X .



<PAGE>

PART I.

ITEM 1.   FINANCIAL STATEMENTS.


                               US Biodefense, Inc.
                            (Formerly Piedmont, Inc.)
                                  BALANCE SHEET
                                  May 31, 2003
                                   (Unaudited)

                                                             Three Months Ended
                                                                May 31, 2003
ASSETS
CURRENT ASSETS:
   Cash                                                         $         0
   Accounts Receivable                                          $
   Other Investments                                            $         0
                                                                ------------
TOTAL CURRENT ASSETS                                            $
ORGANIZATIONAL COSTS, NET                                       $         0
TOTAL ASSETS                                                    $         0
                                                                ===========


LIABILITIES AND STOCKHOLDERS' EQUITY
CURRENT LIABILITIES:
   Accounts Payable                                             $         0
TOTAL CURRENT LIABILITIES                                       $         0
LONG-TERM DEBT                                                  $         0

STOCKHOLDERS' EQUITY:
Preferred stock, $.001 par value,
   authorized 40,000,000 shares;
   no shares issued
Common stock, $.001 par value
   authorized 100,000,000 shares,
   issued and outstanding at
   May 31, 2003, 100,932 shares                                 $       101

Additional paid in Capital                                      $ 3,646,289
Earnings Accumulated During Development Stage                   $(3,656,390)
                                                                ------------
TOTAL STOCKHOLDERS' EQUITY                                      $         0

TOTAL LIABILITIES AND STOCKHOLDERS' EQUITY                      $         0
                                                                ===========

See accompanying notes to interim financial statements



                                       2
<PAGE>

                        US Biodefense, Inc.
                           (Formerly Piedmont, Inc.)
                     STATEMENT OF OPERATIONS
                  Six Months Ended on May 31, 2003
                           (Unaudited)


                                   Three Months    Six Months    For the year
                                   Ended           Ended         Ended
                                   May 31, 2003    May 31, 2003  Nov 30, 2002
                                   ------------    -----------   -----------
INCOME:

Revenue                                   $   0           $   0        $   0
TOTAL INCOME                              $   0           $   0        $   0
                                          =====           =====        =====

EXPENSES:
General, and Administrative               $    0          $    0       $   0
Amortization                              $    0          $    0       $   0
Total Expenses                            $               $            $
Net Profit/Loss(-) From Operations        $               $            $
Interest Income                           $    0          $    0       $   0
INCOME (LOSS) BEFORE INCOME TAXES                         $            $   0
Provision for income tax                  $    0          $    0       $   0
NET INCOME (LOSS)                         $    0          $    0       $   0
                                          ======          ======       =====
NET INCOME (LOSS) PER                     $ 0.00          $ 0.00       $0.00
   SHARE-BASIC AND DILUTED
AVERAGE NUMBER OF SHARES OF
   COMMON STOCK OUTSTANDING              100,932          100,932  10,093,195

See accompanying notes to interim financial statements

<PAGE>
<TABLE>
<CAPTION>


                                          US BIODEFENSE, INC.
                                       (Formerly Piedmont, Inc.)
                                   STATEMENT OF STOCKHOLDERS' EQUITY
                                  Three Months Ended on May 31, 2003
                                              (Unaudited)


                                                                            Additional
                               Preferred             Common Stock             paid-in      Accumulated
                                 Stock          Shares          Amount        capital        loss
                               -----------    -----------    -----------    -----------   -----------
<S>                            <C>            <C>            <C>            <C>           <C>
Balance, November 30, 1997               0     23,298,985         23,299      3,625,897    (3,649,048)


December 15, 1997, issued                          72,000             72
  for services rendered,
  at par value

December 15, 1997, issued
  for fees to prepare proxy
  statement and to amend
  Articles of Incorporation,
  at par value                                 76,000,000         76,000        (76,000)


December 30, 1997, reverse
  stock split, 100-1                          (98,377,119)       (98,377)        98,377

February 6, 1998, issued
  for proposed acquisition
  of Fort Stockton Oil &
  Gas, Inc.                                     8,977,229          8,977         (1,977)

June 9, 1998, issued for
  services rendered                                52,100             52


Net loss, year ended
  November 30, 1998                      0                                                     (8,154)
                               -----------    -----------    -----------    -----------   -----------
Balance, November 30, 1998               0     10,023,195         10,023      3,646,297    (3,657,202)

December 1, 1998, issued for
  services rendered                                60,000             60

August 19, 1999, issued for
  services rendered                                10,000             10

Net loss, year ended
  November 30, 1999                      0                                                       (325)
                               -----------    -----------    -----------    -----------   -----------
Balance, November 30, 1999               0     10,093,195         10,093      3,646,297    (3,657,527)

Net income, year ended
  November 30, 2000                                                                             1,137

Balance, November 30, 2000               0     10,093,195         10,093      3,646,297    (3,656,390)
                               ===========    ===========    ===========    ===========   ===========

Net loss, year ended
  November 30, 2001                      0                                                        -0-
                               -----------    -----------    -----------    -----------   -----------

Balance, November 30, 2001               0     10,093,195         10,093      3,646,297    (3,656,390)
                               ===========    ===========    ===========    ===========   ===========

Net loss, year ended
  November 30, 2002                      0                                                        -0-
                               -----------    -----------    -----------    -----------   -----------

Balance, November 30, 2002               0     10,093,195         10,093      3,646,297    (3,656,390)
                               ===========    ===========    ===========    ===========   ===========


Net income, quarter ended
  February 28, 2003                                                                               -0-

Balance, February 28, 2003               0     10,093,195         10,093      3,646,297    (3,656,390)
                               ===========    ===========    ===========    ===========   ===========

May 15, 2003, reverse
  stock split, 100-1                     0     (9,992,263)        (9,992)         9,992

Net income, quarter ended
  May 31, 2003                                                                                    -0-

Balance, May 31, 2003                    0        100,932    $       101      3,656,289    (3,656,390)
                               ===========    ===========    ===========    ===========   ===========


See accompanying notes to interim financial statements.

                                                   4
</TABLE>

<PAGE>

                           US Biodefense, Inc.
                           (Formerly Piedmont, Inc.)
                      STATEMENTS OF CASH FLOWS
                 Three Months Ended on May 31, 2003
                            (Unaudited)


                              Three Months    Six Months  For the year
                                 Ended           Ended        Ended
                              May 31, 2003   May 31, 2003  Nov 30, 2002
                              ------------   ------------  -----------


CASH FLOWS FROM OPERATING
ACTIVITIES:
Net (Loss) Income:               $   0         $   0        $    0
Decrease (Accts Payable)
Net Cash (Used) In Operating
Activities                       $   0         $   0        $    0

CASH FLOWS FROM INVESTING
ACTIVITIES
Purchase of organizational
Costs                            $  0          $   0        $    0
CASH FLOWS FROM FINANCING
ACTIVITIES
Issuance of common stock for
Cash                             $  0          $   0        $    0

Net Increase in Cash             $  0          $   0        $    0
Cash, Beginning of Period        $  0          $   0        $    0
Cash, End of Period              $  0          $   0        $    0

See accompanying notes to interim financial statements



<PAGE>

                               US Biodefense, Inc.
                            (Formerly Piedmont, Inc.)
                          NOTES TO INTERIM CONSOLIDATED
                              FINANCIAL STATEMENTS

NOTE 1 - HISTORY, ACCOUNTING POLICIES AND PROCEDURES

The Company was incorporated June 29, 1983 under the laws of the State of Utah
as Teal Eye, Inc. On September 7, 1984, the Company merged with Terzon Corp. and
amended its Articles of Incorporation changing the Company name to Terzon Corp.
On September 7, 1984, the Company amended its Articles of Incorporation changing
its name to Candy Stripers Candy Corporation, Inc.. On January 6, 1998, the
Company amended its Articles of Incorporation changing its name to Piedmont,
Inc. On May 13, 2003, the Company amended its Articles of Incorporation changing
its name to US Biodefense, Inc.

The nature of the Company's business was the development of websites, including
consultation and design, for the sale of retail products. The company's website
(www.piedmontcybermall.com) is presently operational but will be shut down
shortly. The Company has changed its direction since the change in management
and ownership. The new Board of Directors is interested in developing,
acquiring, and assisting companies in the biodefense industry.

The Company has adopted the following accounting policies and procedures:

1. The Company uses the accrual method of accounting.

2. Earnings (loss) per share is calculated using a weighted averaged number of
shares of common stock outstanding.

3. The Company has elected a fiscal year ending November 30th.

NOTE 2 - EMPLOYEE STOCK OPTION PLAN

On December 27, 1997, the stockholders approved setting aside 500,000 shares of
common stock for an employee stock bonus plan, the terms of which are to be
determined by the Board of Directors.

NOTE 3 - WARRANTS AND OPTIONS

There are no warrants or stock options outstanding to acquire any additional
shares of common stock of the Company,

NOTE 4 - STOCKHOLDERS' EQUITY.

Common Stock.

The authorized common stock of US Biodefense, Inc. consists of 100,000,000
shares with a par value of $0.001 per share. As of May 31, 2003, US Biodefense,
Inc. had 100,932 shares outstanding.

Preferred Stock.

The authorized Preferred Stock of US Biodefense, Inc. consists of 40,000,000
shares with a par value of $0.001 per share. No preferred shares have been
issued.

NOTE 5 - INCOME TAXES.

There is no provision for income taxes for the period ended May 31, 2002 due to
the zero net income and substantial loss carry forward.

ITEM 2.  PLAN OF OPERATION.

The following discussion should be read in conjunction with the financial
statements of US Biodefense, Inc. and notes thereto contained elsewhere in this
report.

Initial Operation.

Up to the present time, US Biodefense, Inc. has only been in the organizational
phase. Over the next 12 months US Biodefense, Inc. intends to concentrate its
efforts in development and acquisition of businesses in the biodefense industry.
US Biodefense, Inc. will also be seeking to enhance its revenues by consulting
with businesses in the biodefense industry and related fields.

US Biodefense, Inc. will need to raise additional capital in order to continue
its operations. Such financing will probably take the form of a combination of
debt and equity financing. However, there is no guarantee that such financing
will be available at all or on such terms as will be acceptable to US
Biodefense, Inc.

Currently, US Biodefense, Inc. does not plan to make significant equipment
purchases in the next 12 months in order to implement its plan of operation.
Also, it does not plan over such period to significantly change the number of
employees.



<PAGE>

Liquidity and Capital Resources.

During the three month period ended May 31, 2003, US Biodefense, Inc. continued
its status as a development company. US Biodefense, Inc. is continuing to incur
limited development expenses, is deriving no revenues, and has experienced an
ongoing deficiency in working capital. US Biodefense, Inc.'s continued existence
is dependent on its ability to obtain additional financing to proceed with its
plan of operation.

Capital Expenditures.

No material capital expenditures were made during the quarter ended on May 31,
2003.

PART II.

ITEM 1.  LEGAL PROCEEDINGS.

US Biodefense, Inc. is not a party to any material pending legal proceedings
and, to the best of its knowledge, no such action by or against US Biodefense,
Inc. has been threatened.

ITEM 2.  CHANGES IN SECURITIES AND USE OF PROCEEDS.

Not Applicable.

ITEM 3.  DEFAULTS UPON SENIOR SECURITIES.

Not Applicable.

ITEM 4.  SUBMISSION OF MATTERS TO A VOTE OF SECURITY HOLDERS.


           On or about April 1, 2003, Mr. Vincent van den Brink, President and
  Director of Piedmont, Inc. (the "Company"), entered into a stock purchase
  agreement with Mr. David Chin, a natural individual, involving a class of the
  Company's securities registered pursuant to Section 12(g) of the Securities
  Exchange Act of 1934 (the "Exchange Act"). Subsequent to this sale of
  controlling interest, the Company held a special meeting of shareholders on
  April 23, 2003, whereby the following topics were voted upon by the majority
  shareholders:


     1. Change of Name: The shareholders approved the filing of an amendment to
     its articles of incorporation to change its name to U.S. Biodefense, Inc.
     Upon effectiveness of the amendment, the Company will request its ticker
     symbol, currently PDMT, to be changed.

     2. Election of Directors: Vincent van den Brink and Rita Thomas, both of
     whom are officers and directors of the Company, have tendered their
     resignations from their respective positions with the Company. David Chin
     has been elected to serve as the interim President, Secretary, Treasurer
     and Director of the Company.

  On or about May 15, 2003, a majority of the shareholders of the Company
  elected to effect a reverse stock split whereby one post-split share of the
  Company's $0.001 par value common stock will be issued for every 100 pre-split
  shares of the Company common stock held by the shareholders of the Company.

ITEM 5.  OTHER INFORMATION.

Not Applicable

ITEM 6.  EXHIBITS AND REPORTS ON FORM 8-K.

(a)      Reports on Form 8-K.
  During this quarter, the Company filed two Form 8-Ks. The first 8-K was filed
  on April 24, 2003, reporting the sale of a majority interest in the Company to
  Mr. David Chin, the resignation of Vincent van den Brink and Rita Thomas, the
  interim appointment of Mr. Chin as President, Secretary, Treasurer, and
  Director, and the approval of the company name change to US Biodefense, Inc.
  The second 8-K was filed on June 9, 2003, reporting the change in CPA
  accountancy firms, the election of David Chin as President, Secretary,
  Treasurer, and Director, and that a majority of the shareholders of the
  Company have elected to effect a reverse stock split whereby one post-split
  share of the Company's $0.001 par value common stock will be issued for every
  100 pre-split shares of the Company's common stock held by the shareholders of
  the Company. Additionally, the Company has submitted a request with Nasdaq
  Market Integrity to change its ticker symbol.

<PAGE>



(b)      Exhibits included or incorporated by reference herein:

Exhibit 3: Certificate of Amendment to Articles of Incorporation re Name Change

SIGNATURE

                            CERTIFICATION PURSUANT TO
                  SECTION 302 OF THE SARBANES-OXLEY ACT OF 2002

       In connection with the Quarterly Report of US Biodefense, Inc. (formerly
Piedmont, Inc.) (the "Registrant") on Form 10-QSB for the quarterly period
ending May 31, 2003 as filed with the Securities and Exchange Commission on the
date hereof (the "Report"), I, David Chin, Chairman of the Board of Directors,
President, and Chief Executive Officer of the Registrant, certify, pursuant to
Section 302 of the Sarbanes-Oxley Act of 2002, that:


     1. I have reviewed this quarterly report on Form 10-QSB of the Registrant;


     2. Based on my knowledge, this quarterly report does not contain any untrue
statement of a material fact or omit to state a material fact necessary to make
the statements made, in light of the circumstances under which such statements
were made, not misleading with respect to the period covered by this quarterly
report;


     3. Based on my knowledge, the financial statements, and other financial
information included in this quarterly report, fairly present in all material
respects the financial condition, results of operations and cash flows of the
Registrant as of, and for, the periods presented in this quarterly report;


     4. I am responsible for establishing and maintaining disclosure controls
and procedures (as defined in Exchange Act Rules 13a-14 and 15d-14) for the
Registrant and I have:


     a) designed such disclosure controls and procedures to ensure that material
     information relating to the Registrant, including its consolidated
     subsidiaries, is made known to me by others within those entities,
     particularly during the period in which this quarterly report is being
     prepared;

     b) evaluated the effectiveness of the Registrant's disclosure controls and
     procedures as of a date within 90 days prior to the filing date of this
     quarterly report (the Evaluation Date); and

     c) presented in this quarterly report our conclusions about the
     effectiveness of the disclosure controls and procedures based on my
     evaluation as of the Evaluation Date;


     5. I have disclosed, based on our most recent evaluation, to the
Registrant's auditors and the audit committee of Registrant's board of directors
(or persons performing the equivalent function):


     a) all significant deficiencies in the design or operation of internal
     controls which could adversely affect the Registrant's ability to record,
     process, summarize and report financial data and have identified for the
     Registrant's auditors any material weaknesses in internal controls; and


     b) any fraud, whether or not material, that involves management or other
     employees who have a significant role in the Registrant's internal
     controls; and


     6. I have indicated in this quarterly report whether or not there were
significant changes in internal controls or in other factors that could
significantly affect internal controls subsequent to the date of our most recent
evaluation, including any corrective actions with regard to significant
deficiencies and material weaknesses.



<PAGE>

Pursuant to the requirements of Section 13 or 15(d) of the Securities Exchange
Act of 1934, the Registrant has duly caused this report to be signed on its
behalf by the undersigned, thereunto duly authorized.

                                    US Biodefense, Inc.

Dated: July 14, 2003                By: David Chin
                                        ---------------------
                                        David Chin, President